4296
W. N. Washburn et al. / Bioorg. Med. Chem. Lett. 17 (2007) 4290–4296
Dejneka, T. C.; Wang, T. C.; Merchant, Z.; Morella, M.;
13. Receptor binding assays were run in triplicate with
membranes prepared from CHO cells expressing the
three cloned human b receptors in the presence of 125I-
iodocyanopindolol.14 b3 AR agonist activity was
assessed by measurement of cAMP accumulation levels
in CHO membranes expressing human b3 AR.15 IA is
given as a percentage of the maximal stimulation with
isoproterenol.
14. All compounds were evaluated using the truncated human
b3 adrenergic receptor reported by Emorine, L. T.;
Marullo, S.; Briend-Sutren, M. M.; Patey, G.; Tate, K.;
Delavier-Klutchko, C.; Strosberg, A. D. Science 1989,
245, 1118.
15. Sher, P. M.; Fisher, L. G.; Skwish, S.; Michel, I. M.;
Seiler, S. M.; Washburn, W. N.; Dickinson, K. E. J. Med.
Chem. Res. 1997, 7, 109.
16. Spectral data were fully consistent with structures.
17. Beeley, L. J.; Berge, J. M.; Chapman, H.; Dean, D. K.;
Kelly, J.; Lowden, K.; Kotecha, N. R.; Morgan, H. K. A.;
Rami, H. K.; Thompson, M.; Vong, A. K. K.; Ward, R.
W. Bioorg. Med. Chem. Lett. 1997, 7, 219.
Arbeeny, C. M.; Harper, T. W.; Slusarchyk, D. A.;
Skwish, S.; Russell, A. D.; Allen, G. T.; Tesfamariam, B.;
Frohlich, B. H.; Abboa-Offei, B. E.; Cap, M.; Waldron, T.
L.; George, R. J.; Young, D.; Dickinson, K. E.; Seymour,
A. A. Bioorg. Med. Chem. Lett. 2004, 14, 3525.
4. Himms-Hagen, J.; Ricquier, D. In Handbook of Obesity;
Bray, G. A., Bouchard, C., James, W. P. T., Eds.; Marcel
Dekher: New York, 1998; p 415.
5. Larsen, A. A.; Gould, W. A.; Roth, H. R.; Comer, W. T.;
Uloth, R. H. J. Med. Chem. 1967, 10, 462.
6. (a) Guengerich, F. P.; Yun, C. H.; Macdonald, T. L.
J. Biol. Chem 1996, 271, 27321; (b) Guengerich, F. P.
Chem. Res. Toxicol. 2001, 14, 611.
7. Hu, B.; Ellingboe, J.; Han, S.; Largis, E.; Mulvey, R.;
Oliphant, A.; Sum, F.-W.; Tillet, J. J. Med. Chem. 2001, 44,
1456.
8. LD100 for mice was 57 lg/kg of 2 administered iv; iv doses
of 0.5–5.7 lg/kg produced progressively more pronounced
piloerection; 0.05 lg/kg was a no effect dose. This dose
dependent response suggested that piloerection following
iv administration of 10 mg/kg of 1 during the murine
safety screen was indicative of 0.01–0.1% of the dose being
converted to 2. A few compounds, such as 1f, were lethal
at 10 mg/kg but not at 1 mg/kg implying that metabolic
conversion to 2 was ꢀ0.1–1%.
18. In 95% EtOH at 20 °C, t1/2 was ꢀ40 min to presumably
generate quinones.
19. Larson, A. A.; Gould, W. A. US Patent 1,171,477.
20. Wu, G.; Cai, Z. W.; Bednarz, M. S.; Kocy, O.; Gavai, A.
V.; Godfrey, J. D.; Washburn, W. N.; Sher, P. M.
J. Comb. Chem. 2005, 7, 99.
21. Stereochemical preferences had not previously been
addressed in the few reports concerning arylpropanol-
amine as adrenergic ligands.22
9. Typically, a 100 lM solution of compounds of structure 1
was incubated for 3 h in pH 7.4 phosphate buffer (0.1 M)
containing African green monkey hepatic microsomes
(3 mg/mL protein) and 3 mM NADPH whereupon the
protein was precipitated by addition of 2 volumes MeCN
prior to determination of the conversion to 2 by LC/MS.
Since control studies entailing incubation of compounds
of structure 1 as described above in the absence of
NADPH generated minuscule amounts of 2, solvolytic
release of 2 due to chemical instability of 1 after
protonation was of minimal importance.
22. (a) Fuhrer, W.; Ostermayer, F.; Zimmermann, M.; Meier,
M.; Muller, H. J. Med. Chem. 1984, 27, 831; (b) Lo¨vgren,
¨
K.; Hedberg, H.; Nilsson, J. L. G. J. Med. Chem. 1981, 24,
ˇ
´
ˇ
451; (c) Alderova, E.; Trcka, V.; Smejkal, V.; Protiva, M.
Collect. Czech. Chem. Commun. 1969, 34, 479; (d) WO
2000/012462; (e) WO 1999/051564.
23. Absolute stereochemistry of 15f assigned by X-ray
crystallography.
10. Subsequently during clinical studies with BMS-196085
(1c), BMS-194449 (1b), and BMS-201620 (1j) dose
dependent incidences of sweaty palms, flushing, and
piloerection, all classic manifestations of an a adrenergic
agonist, as well as detection of trace levels of 2 validated
these concerns regarding metabolic liberation of 2.
11. (a) Kirk, K. L.; Cantacuzene, D.; Creveling, C. R. Biomed.
Aspects Fluorine Chem. 1982, 75; (b) Brasili, L.; Cantala-
messa, F.; Picchio, M. T.; Quaglia, W. Eur. J. Pharm.
1987, 144, 141.
24. b1 IA was determined by measuring the acceleration in
contraction of spontaneously beating guinea pig atria
relative to that induced by isoproterenol.25 b2 IA was
determined by measuring relaxation of guinea pig trachea
rings submaximally contracted with carbacol relative to
that induced by isoproterenol.
25. Tesfamariam, B.; Allen, G. T. Br. J. Pharmacol. 1994, 112,
55.
26. Lipworth, B. J.; McFarlane, L. C.; Coutie, W. J.;
McDevitt, D. Eur. J. Clin. Pharmacol. 1989, 37,
297.
12. Hieble, J. P.; Hehr, A.; Li, Y.; Ruffolo, R. R. Proc.
Western Pharmacol. Soc. 1998, 41, 225.